Tifluadom

Tifluadom is a benzodiazepine derivative with anxiolytic, antidepressant, antipsychotic, and anticonvulsant properties. It was developed by Hoffmann-La Roche in the 1980s and is used in scientific research. Tifluadom is a rare example of a benzodiazepine antagonist. It is the only selectively kappa opioid receptor agonist to have been researched in humans; the kappa opioids are known to have dysphoric, hallucinogenic, analgesic, and anxiolytic properties.

Pharmacology

Tifluadom is a kappa opioid receptor agonist, specifically, it is selective for the κ2 subtypes. It has potent analgesic and diuretic effects but without a corresponding occurrence of side effects. Because of this it has potential for broad clinical use, including in the treatment of rheumatism and arthritis. It has been found to be effective in the treatment of a variety of conditions, including acute gout, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, sciatica, low back pain, and osteoarthrosis.

Chemistry

Tifluadom is a benzodiazepine but it is not marketed as such, it is sold as a kappa opioid receptor agonist. Tifluadom is a quinazolinone derivative and is related to other benzodiazepine drugs such as flurazepam and brotizolam.

History

Tifluadom was first synthesized in the 1980s by Hoffmann-La Roche and is one of the few kappa opioid receptor agonists to have been synthesized.

See also

• Benzodiazepine
• Kappa opioid receptor
• Hoffmann-La Roche

Tifluadom Resources
Latest articles Most recent articles Ongoing trials	Wikipedia